CEA, BioAssay(TM) ELISA Kit (Carcinoembryonic Antigen-related Cell Adhesion Molecule 5, Carcinoembryonic Antigen, Meconium Antigen 100, CD66e, CEACAM5)

Carcinoembryonic antigen (CEA) was first described in 1965 by Gold and Freedman when they identified an antigen that was present in both fetal colon and colon adenocarcinoma but that appeared to be absent from healthy adult colon. CEA is a glycoprotein containing approximately 50% carbohydrate with a molecular weight of 180kD. CEA and related genes make up the CEA family belonging to the immunoglobulin superfamily. In humans, the carcinoembryonic antigen family consists of 29 genes, 18 of which are normally expressed.\n\nCEA has proven to be a suitable target antigen for the detection of primary and metastatic colorectal and some other carcinomas. Although sera from healthy individuals and from patients with other diseases generally had low levels of CEA, CEA is one of the most widely used tumor markers worldwide. Its main application is mostly in gastrointestinal cancers, especially in colorectal malignancy. CEA assays are now generally accepted clinically as a useful and cost- efficient tool in monitoring of colon cancer following surgery.\n\nIntended Use:\nHuman Carcinoembryonic Antigen (human CEA) ELISA kit is to be used for the in vitro quantitative determination of human CEA in human serum, human plasma, cell lysate and buffered solution. The assay will recognize native CEA. This kit has been configured for research use only and is not to be used in diagnostic procedures.\n\nSensitivity:\nThe minimal detectable dose of human CEA was calculated to be 0.15ng/ml, by subtracting two standard deviations from the mean of 10 zero standard replicates (ELISA buffer, S0) and intersecting this value with the standard curve obtained in the same calculation.\n\nSpecificity:\nThe following substances were tested and found to have no cross-reactivity: human\n\nTest Principle:\nThe design of this assay is based on a sandwich Enzyme-Linked Immunosorbent Assay (ELISA). The microtiter plate provided in this kit has been pre-coated with a monoclonal antibody specific to human CEA. Samples are pippetted into these wells. Nonbound CEA and other components of the sample should be removed by washing, then biotin-conjugated monoclonal antibody specific to CEA added. In order to quantitatively determine the amount of CEA present in the sample, Avidin conjugated to Horseradish Peroxidase (HRP) should be added to each microplate well. The final step, a TMB-substrate solution added to each well. Finally, a sulfuric acid solution is added and the resulting yellow colored product is measured at 450nm. Since the increases in absorbency is directly proportional to the amount of captured CEA.\n\nKit Components:\nMicroplate: 1x96 wells\nIncubation buffer: 1x30ml\nWashing buffer, (10x): 1x100ml\nStandard protein: 1 glass vial lyophilized\nStandard/sample dilution buffer: 1x25ml\nSecond antibody: 1 glass vial lyophilized\nAV-HRP: 1x150ul\nSecondary antibody/AV-HRP dilution buffer: 1x25ml\nSubstrate (TMB): 1x20ml\nStop solution: 1x20ml\n\nStorage and Stability:\nStore components at 4 degrees C. Stable for at least 6 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

C1300-06A

Size

96Tests

Applications

ELISA

References

1. Duffy MJ. 2001, Clin Chem. 47(4):624-630. 2. Hammarstrom S. 1999, Semin Cancer Biol. 9(2):67-81. 3. Ducker TP and Skubitz KM. 1992, J Leukoc Biol. 52(1):11-16.